EGFR and non-small cell lung carcinoma: Furthermore, the treatment of NSCLC—harboring the Epidermal Growth Factor Receptor (EGFR) wild-type phenotype or its mutant—with Apigenin suppressed CD26 expression and the interplay of downstream signaling such as p-AKT and Snail/Slug, resulting in inhibition of EMT-mediated invasion in vitro [47].